- Open Access
Novel culture media enhances mononuclear cells from patients with chronic limb-threatening ischemia to increase vasculogenesis and anti-inflammatory effect
Stem Cell Research & Therapy volume 12, Article number: 520 (2021)
Quality and Quantity culture media (QQ culture media) was reported to enhance vasculogenesis and angiogenesis function of mononuclear cells (MNCs) from healthy volunteers. In this study, MNCs from chronic limb-threatening ischemia (CLTI) patients were cultured in QQ culture media, and then investigated for angiogenesis-related phenotype and function.
Patients aged ≥ 18 years with CLTI caused by atherosclerosis of the lower extremities were prospectively recruited at Siriraj Hospital (Bangkok, Thailand) during July 2017–December 2018. Peripheral blood mononuclear cells (PBMNCs) were isolated from peripheral blood. PBMNCs were cultured in either QQ culture media or standard culture media. The number of CD34+CD133+ cells, CD206+ cells, CD4+CD25+CD127+ cells, colony formation assay, and human umbilical vein endothelial cell (HUVEC) tube formation assay in MNCs were compared between those cultured in QQ culture media and those cultured in standard culture media.
Thirty-nine patients were included with a mean age of 69 ± 11 years. Diabetes mellitus was found in 25 (64%) patients. The percentage of CD34+CD133+ progenitor cells in MNCs cultured in QQ culture media and in MNCs cultured in standard culture media was 4.91 ± 5.30% and 0.40 ± 0.46%, respectively (p < 0.0001). The percentage of CD206+ cells in MNCs cultured in QQ culture media and in MNCs cultured in standard culture media was 19.31 ± 11.42% and 4.40 ± 2.54%, respectively (p < 0.0001). The percentage of inactive population of T regulatory cells (CD4+CD25+CD127+ cells) in MNCs cultured in standard culture media and in MNCs cultured in QQ culture media was 14.5 ± 10.68% and 1.84 ± 1.37%, respectively (p < 0.0001). The total number of colony-forming units from MNCs cultured in QQ culture media and in MNCs cultured in standard culture media was 8.86 ± 8.35 of 2 × 105 cells/dish, and 0.58 ± 1.05 of 2 × 105 cells/dish, respectively (p < 0.0001). The mean intensity of Dil-Ac-LDL uptake that incorporated into the HUVEC forming tube was 1.37 ± 0.88 in MNCs cultured in QQ culture media, and 0.78 ± 0.41 in MNCs cultured in standard culture media. (p < 0.0003).
MNCs from CLTI patients that were cultured in QQ culture media had a significantly higher number of CD34+CD133+ cells and anti-inflammatory cells, and higher angiogenesis-related function compared to MNCs cultured in standard culture media.
Chronic limb-threatening ischemia (CLTI), which is an advanced stage of peripheral arterial disease, is characterized by severe occlusion of the arteries that markedly reduces blood flow to the lower extremities . Symptoms and signs of CLTI include pain at rest, non-healing ulcer, and tissue gangrene leading to limb amputation—all of which are associated with high morbidity and mortality .
Endothelial progenitor cells (EPCs) were isolated and shown to be effective for promoting angiogenesis both in vitro and in vivo . Several studies showed cell-based therapy using bone marrow or peripheral blood mononuclear cells (PBMNCs) to promote vascular angiogenesis to be safe and effective [3,4,5,6]. However, the number of EPCs in bone marrow and in PBMNCs is less than 0.01% and 0.1%, respectively [4, 7,8,9,10]. Moreover, the process of increasing the number of EPCs for effective therapeutic angiogenesis is time consuming and requires well-trained personnel [4, 7,8,9,10].
In 2014, Masuda et al. developed and reported a new culture media for MNCs that they named Quality and Quantity culture media (QQ culture media) . QQ culture media was shown to enhance vasculogenesis and angiogenesis function of MNCs from healthy volunteers . The MNCs cultured in QQ culture media (QQ-MNCs) showed higher therapeutic potential in vascular and tissue regeneration than the PBMNCs cultured in standard culture media [11, 12]. However, the effect of QQ culture media on MNCs from CLTI patients has not been investigated. In this study, PBMNCs from CLTI patients were cultured in QQ culture media, and then evaluated for their angiogenesis-related phenotype and function. Those results were then compared with those of PBMNCs cultured in standard culture medium.
Materials and methods
All patients aged 18 years or older with CLTI caused by atherosclerosis of the lower extremities who attended the CLTI clinic of the Division of Vascular Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand during July 2017 to December 2018 were prospectively invited to join this study. To be eligible for inclusion, patient candidates had to have at least one of the following presenting symptoms: ischemic rest pain, non-healing ulcer, or gangrene of lower extremity. Patients having other causes of CLTI, such as thromboangiitis obliterans, autoimmune disease, or thrombosed aneurysm, were excluded. Patients with severe infection and those not willing to join the study were also excluded. Patient demographic and clinical data, including age, gender, body mass index (BMI), comorbidity, and medical history of CLTI, were collected and recorded.
The study protocol was approved by the Ethical Review Committee of the Siriraj Institutional Review Board (COA No. 207/2560 [EC4]), and written informed consent was obtained from all patients.
Fifteen milliliters (ml) of peripheral blood were collected by venous puncture of superficial vein at forearm. PBMNCs were isolated by density gradient centrifugation using Lymphocyte Separation Solution (Sigma-Aldrich Corporation, St. Louis, MO, USA). PBMNCs at a concentration at 2 × 106 cells/2 ml were cultured either in QQ culture media  or in standard culture media  The cells were cultured in a 6-well Primaria dish (BD Biosciences, San Jose, CA, USA) for 7 days [11, 13].
QQ culture media
The components of QQ culture media include the following: Stem Line II Solution (#S0192; Sigma-Aldrich) supplemented with five recombinant human proteins, including 100 ng/m of stem cell factor (SCF) (cat. no. #300-07; PeproTech, Cranbury, NJ, USA), 20 ng/ml of thrombopoietin (TPO) (#300-18; PeproTech), 100 ng/ml of Flt-3 ligand (#300-19; PeproTech), 50 ng/ml of vascular endothelial growth factor (VEGF) (#100-20; PeproTech), and 20 ng/ml of interleukin (IL)-6 (#200-06; PeproTech) .
Standard culture media
Standard culture media is composed of 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) and Roswell Park Memorial Institute (RPMI)-1640 Medium (Gibco; Thermo Fisher Scientific) [11, 13].
Phenotypic analysis of progenitor cells, T regulatory cells, and M2 macrophages
After 7 days of cell culture, the cultured cells were harvested and washed with 2% FBS and 0.02% NaN3 phosphate-buffered saline (PBS) 2 times. Cells suspended in 2 mmol/L of EDTA/0.2% BSA/ PBS buffer were incubated after the addition of 10 µl of FcR blocking reagent at 4 °C for 30 min. The cells were then stained with markers of progenitor cells (CD34+CD133+ cells), M2 macrophages (CD206+ cells), and inactivated regulatory T cells (CD4+CD25+CD127+ cells) using a combination of monoclonal antibodies. In this study, two separate panels were used for phenotypic analysis. The first panel was used for the phenotypic analysis of progenitor cells and M2 macrophages. Cells were incubated with 5 µl of each mAb at 4 °C for 30 min. The mAbs included CD34-FITC (#343504; BioLegend, San Diego, CA, USA), CD11c-PE (#371504; BioLegend), CD133-APC (#372806; BioLegend), CD3-PE-Cy7 (300420; BioLegend), CD206-APC-Cy7 (#321119; BioLegend), and CD11b-PerCP Cy5.5 (#101228; BioLegend). The cells were then washed with 2% FBS and 0.02% NaN3 phosphate-buffered saline (PBS) 2 times and fixed with 1% paraformaldehyde (Sigma-Aldrich) in PBS. The cells were assessed using a BD LSR Fortessa Flow Cytometer™ (BD Biosciences, San Jose, CA, USA) [11, 14].
The second panel was used for the phenotypic analysis of inactivated T regulatory (CD4+CD25+CD127+) cells. Cells were incubated with 5 µl of each mAb at 4 °C for 30 min. The mAbs included CD25-PE (#302606; BioLegend), CD127-APC (#351316; BioLegend), CD3-Pe-Cy7 (#300420; BioLegend), and CD4-APC-Cy7 (#300518; BioLegend) [11, 14]. All experiments were performed in triplicate. The numbers of CD34+CD133+ cells, CD206+ cells, and CD4+CD25+CD127+ cells in PBMNCs cultured in QQ culture media and PBMNCs cultured in standard culture media were then compared.
Endothelial progenitor cell (EPC) colony formation assay (EPC-CFA)
PBMNCs were harvested at a concentration of 1 × 105 cells/ml and resuspended with 30% FBS/PBS 200 µl. The following recombinant human cytokines were then added to the cells: human SCF (#300-07; PeproTech) at a concentration of 66.7 ng/ml; human VEGF (#100-20; PeproTech) at a concentration of 33.3 ng/ml; human IL3 (#200-03; PeproTech) at a concentration of 13.3 ng/ml; human IGF-1 (#100-11; PeproTech) at a concentration of 33.3 ng/ml; human FGF Basic (#100-18B; PeproTech) at a concentration of 33.3 ng/ml; and, human EGF (#100-15; PeproTech) at a concentration of 33.3 ng/ml. The cell mixture was resuspended with complete MethoCult™ media (#04236; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada) at a final volume of 2 ml, and then cultured in a 37 °C environment for 14 days . Endothelial progenitor cell (EPC) colony forming cells (EPC-CFCs) were assessed under phase-contrast light microscopy (Eclipse TE300; Nikon Instruments, Tokyo, Japan). A colony was defined as the presence of at least 50 cells . All experiments were performed in triplicate. The numbers of colonies of PBMNCs cultured in QQ culture media and in standard culture media were compared.
Tube formation assay
PBMNCs were labeled with 20 µg/ml of acetylated low-density lipoprotein and 1,10-dioctadecyl-3,3,30,30-tetramethyl-indocarbocyanine perchlorate (Dil-Ac-LDL) (Biomedical Technologies, Inc., Stoughton, MA, USA) at a concentration of 4 × 104 cells/500 µl for 30 min in a 37 °C CO2 incubator. The PBMNCs were centrifuged down at 400 g for 10 min followed by washing with 2% FBS/PBS and suspension in 2% FBS/PBS at a concentration of 1 × 103 cells/50 µl. The labelled PBMNCs were then cocultured with human umbilical vein endothelial cells (HUVECs) at an MNC-to-HUVEC ratio of 1 × 103-to-1.5 × 104 cells in a final volume of 100 µl. The cell mixture was incubated in a 37 °C water bath, and then 100 µl of the cell mixture was transferred into a pre-coated Matrigel (thin coat method) 50 µl/well in 96-well plates and incubated at 37 °C in a CO2 incubator for 10 h. The assessment of tube formation was performed using a Nikon Ti-S Intensilight Ri1 NIS-D inverted fluorescence microscope (Nikon Instruments). All experiments were performed in triplicate. The intensity of fluorescence from incorporated labeled PBMNCs from QQ culture media and from standard culture media in HUVECs was compared .
All statistical analyses were performed using Prism 6 software (GraphPad Software, Inc., San Diego, CA, USA). Student's t-test was used for phenotypic analysis of progenitor cells, T regulatory cells, and M2 macrophages, and to compare colony formation and tube formation between MNCs cultured in QQ culture media and MNCs cultured in standard culture media. A p-value less than 0.05 was considered to be statistically significant.
Thirty-nine patients with chronic CLTI caused by atherosclerosis of the lower extremities were included. The mean age of study patients was 69 ± 11 years. There were 20 female and 19 male patients. Diabetes mellitus was found in 25 (64%) patients, and 1 (2.5%) patient reported being a smoker. Hypertension was found in 25 (64%) patients, and dyslipidemia was identified in 26 (67%) patients. Rest pain was reported by 6 (15%) patients. Gangrene was identified in 25 (64%) patients, and non-healing ulcer was found in 8 (21%) patients. The average ankle-brachial index (ABI) was 1.03 ± 0.71.
Percentage of CD34+CD133+ progenitor cells in PBMNCs
The percentage of CD34+CD133+ progenitor cells was significantly higher in PBMNCs cultured in QQ culture media than in PBMNCs cultured in standard culture media (4.91 ± 5.30% vs. 0.40 ± 0.46%, p < 0.0001) (Fig. 1 and Table 1).
Percentage of CD206+ cells in PBMNCs
The percentage of CD206+ cells was significantly higher in PBMNCs cultured in QQ culture media than in PBMNCs cultured in standard culture media (19.31 ± 11.42% vs. 4.40 ± 2.54%, p < 0.0001) (Fig. 2, Table 1).
Percentage of inactivated regulatory T cells (CD4+CD25+CD127+ cells) in PBMNCs
The percentage of inactivated T regulatory cells (CD4+CD25+CD127+ cells) in PBMNCs cultured in standard culture media was 14.5 ± 10.68%. In contrast, the percentage of CD4+CD25+CD127+ cells in PBMNCs cultured in QQ culture media was 1.84 ± 1.37%. The percentage of inactivated T regulatory cells in PBMNCs cultured in QQ culture media was significantly lower (p < 0.001) (Fig. 3, Table 1). A lower number of inactivated regulatory T cells was considered to reflect the anti-inflammatory effect of QQ-MNCs.
EPC-CFA in PBMNCs
The total number of CFUs from PBMNCs cultured in QQ culture media and PBMNCs cultured in standard culture media was 8.86 ± 8.35 of 2 × 105 cells/dish and 0.58 ± 1.05 of 2 × 105 cells/dish, respectively. The total number of CFUs in PBMNCs cultured in QQ culture media was significantly higher than the total number observed in standard culture media-cultured PBMNCs (p < 0.001) (Fig. 4 and Table 1).
Tube formation assay in PBMNCs
The mean intensity of Dil-Ac-LDL uptake that incorporated into the HUVEC forming tube was 1.37 ± 0.88 in PBMNCs cultured in QQ culture media, and 0.78 ± 0.41 in PBMNCs cultured in standard culture media. Dil-Ac-LDL uptake was significantly higher in PBMNCs cultured in QQ culture media. (p < 0.0003) (Fig. 5, Table 1).
In this study, we investigated the angiogenesis-related phenotype and function of PBMNCs from CLTI patients that were cultured in QQ culture media (QQ-MNCs), which was developed and published by Musuda et al. . Our results showed that QQ culture media enhanced angiogenesis, yielded more stem cell progenitor cells, and increased the anti-inflammatory cell population—all compared to the results observed from PBMNCs cultured in standard culture media. Those observed characteristics suggest the potential of QQ-MNCs as a novel therapeutic approach for treating CLTI patients. Most patients with CLTI caused by atherosclerosis have impaired regenerative progenitor cell function [11, 16]. Moreover, diabetes mellitus type II leads to high inflammation and reduced regenerative capability of the vascular system [2, 7, 11, 12, 17].
Several studies have reported aging or older age status to be associated with very high titer of inflammatory cytokines, such as TNF-α and IFN-γ. Both of these cytokines can hinder the regenerative function of progenitor cells. The cause of high expression of inflammatory cytokines in older adults is impaired regulatory T cell function [18, 19].
In vitro and animal study QQ-MNCs from healthy patients demonstrated high vasculogenic conditioning . In the present study, we studied QQ-MNCs from CLTI patients. Most patients in our study were aged > 70 years, and 63% of our patients had diabetes mellitus. PBMNCs from these CLTI patients demonstrated high vasculogenic conditioning after culturing in QQ culture media.
In CLTI patients, the number of CD34+CD133+ progenitor cells, which are considered to be vasculogenic progenitor cells that play an important role in angiogenesis, decreased [11, 20, 21]. In contrast, we found that QQ-MNCs from CLTI patients had a higher number of CD34+CD133+ cells. Masuda et al. reported that QQ-MNCs exhibited slightly increased kinase insert domain receptor (KDR)+ cells compared to PBMNCs . However, they found the population of CD31+ cells in QQ-MNCs and PBMNCs to be comparable .
Previous study found cell populations of QQ-MNCs not only to be increased in CD34+ or CD133+ cell populations (which indicates an expanded population of immature EPCs), but also to be increased in CD105+ or CD146+ cell populations (which is indicative of EPC expansion and differentiation) . These data suggest that QQ culture promotes EPC expansion and differentiation.The QQ-MNCs in our study also demonstrated a significantly greater number of M2 macrophages (CD206, anti-inflammatory macrophages), and significantly less inactivated regulatory T cells (CD4+CD25+CD127+ cells). The CD4+CD25+CD127± phenotype represents a T regulatory subset of T cells, and it plays an important role in controlling immune regulation, suppressing the immune system, and also in controlling the level of inflammatory cytokine release [11, 20]. A recent study reported a relationship between CD4+CD25+CD127± and FoxP3 level, which is considered to be immune suppression population of T regulatory cells [22, 23]. CD4+CD25+CD127+ cells were reported to be associated with low expression of FoxP3 in T regulatory cells, and they are considered to be inactive T regulatory cells that play a role in immune regulation [22, 23]. The results of our study showed the number of CD4+CD25+CD127+ cells to be lower in QQ-MNCs than in PBMNCs cultured in standard culture media. This finding suggests that QQ culture media could activate the regulatory function of T regulatory cells of PBMNCs, which effectuated the suppression of inflammation [11, 23, 24]. These findings suggest that QQ-MNCs yield increased numbers of active regulatory T cells, and that they promote the development of anti-inflammatory cell population, including M2 macrophages .
Moreover, QQ-MNCs from CLTI patients had high angiogenesis-related function as exhibited by colony formation assay and tube formation assay, as shown in Figs. 4 and 5, respectively. Previous study reported that EPC-CFCs were derived from CD34+ cells because CD34+ cell-depleted MNCs did not yield EPC colony; however, CD34+ MNCs after QQ culture contained EPC-CFCs . So, the higher number CD34+ cells in QQ-MNCs in our study might be the cause of the higher number of EPC-CFCs from QQ-MNCs compared to the number coming from PBMNCs.
Although benefit of autologous intramuscular injection of MNCs in no-option CLTI has been reported, a recent meta-analysis did not show a clear benefit of mononuclear cell injection on clinical outcomes in CLTI patients [25, 26]. This could be due to the low quantity and low quality of MNCs from CLTI patients . Our study showed that QQ-MNCs from CLTI patients had a significantly high number of CD34+CD133+ cells, a significantly higher number of anti-inflammatory cells, and significantly higher angiogenesis-related function compared to PBMNCs in in vitro study. The clinical benefit of QQ-MNCs should now be evaluated in in vivo study. As another option for treating CLTI patients with stem cells, some researchers are studying allogeneic mesenchymal stem cell (MSCs) for treating CLTI [28,29,30]. Nevertheless, future high-quality large clinical studies are needed to prove the efficacy of MSCs in the treatment of CLTI.
There are some limitations of this research. QQ-MNCs cultured in a HUVEC tube formation assay is a weak indicator of efficient vasculogenic power in vivo. Tube formation assay with CD34+/CD133+ cells from QQ-MNCs should be further studied in vitro, and further study of QQ-MNCs for cell-based therapy should be conducted in vivo using intramuscular injection of QQ-MNCs from CLTI patients into the limbs of mice whose arteries were ligated.
QQ-MNCs from CLTI patients had a significantly higher number of CD34+CD133+ cells, a significantly higher number of anti-inflammatory cells, and significantly higher angiogenesis-related function compared to MNCs cultured in standard culture media as demonstrated by both colony formation unit assay and HUVEC tube formation assay.
Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Quality and quantity
Chronic limb-threatening ischemia
Peripheral blood mononuclear cells
Human umbilical vein endothelial cell
Endothelial progenitor cells
Fetal bovine serum
Acetylated low-density lipoprotein and 1,10-dioctadecyl-3,3,30,30-tetramethyl-indocarbocyanine perchlorate
Average ankle-brachial index
Tumor necrosis factor
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5-67.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–7.
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–24.
Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg. 2011;53(2):445–53.
Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925–34.
Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360(9331):427–35.
Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res. 2013;112(9):1288–302.
Ishida A, Ohya Y, Sakuda H, Ohshiro K, Higashiuesato Y, Nakaema M, et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circ J. 2005;69(10):1260–5.
Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28(9):2155–60.
Frangogiannis NG. Cell therapy for peripheral artery disease. Curr Opin Pharmacol. 2018;39:27–34.
Masuda H, Tanaka R, Fujimura S, Ishikawa M, Akimaru H, Shizuno T, et al. Vasculogenic conditioning of peripheral blood mononuclear cells promotes endothelial progenitor cell expansion and phenotype transition of anti-inflammatory macrophage and T lymphocyte to cells with regenerative potential. J Am Heart Assoc. 2014;3(3):e000743.
Tanaka R, Masuda H, Fujimura S, Ito-Hirano R, Arita K, Kakinuma Y, et al. Quality-quantity control culture enhances vasculogenesis and wound healing efficacy of human diabetic peripheral blood CD34+ cells. Stem Cells Transl Med. 2018;7(5):428–38.
Honge BL, Petersen MS, Olesen R, Moller BK, Erikstrup C. Optimizing recovery of frozen human peripheral blood mononuclear cells for flow cytometry. PLoS ONE. 2017;12(11):e0187440.
Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315–9.
Burt RK, Testori A, Oyama Y, Rodriguez HE, Yaung K, Villa M, et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant. 2010;45(1):111–6.
van Royen N, Schirmer SH, Atasever B, Behrens CY, Ubbink D, Buschmann EE, et al. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation. 2005;112(7):1040–6.
Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586.
Fessler J, Ficjan A, Duftner C, Dejaco C. The impact of aging on regulatory T-cells. Front Immunol. 2013;4:231.
Zabinska M, Krajewska M, Koscielska-Kasprzak K, Jakuszko K, Bartoszek D, Myszka M, et al. CD4(+)CD25(+)CD127(-) and CD4(+)CD25(+)Foxp3(+) regulatory T cell subsets in mediating autoimmune reactivity in systemic lupus erythematosus patients. Arch Immunol Ther Exp (Warsz). 2016;64(5):399–407.
Fritzenwanger M, Lorenz F, Jung C, Fabris M, Thude H, Barz D, et al. Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure. Eur J Med Res. 2009;14(3):113–7.
Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006;59(1):15–26.
Hartigan-O’Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 2007;319(1–2):41–52.
Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701–11.
Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circ Res. 2017;120(8):1326–40.
Sermsathanasawadi N, Pruekprasert K, Chruewkamlow N, Kittisares K, Warinpong T, Chinsakchai K, et al. Peripheral blood mononuclear cell transplantation to treat no-option critical limb ischaemia: effectiveness and safety. J Wound Care. 2021;30(7):562–7.
Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89(1):E1-7.
Putman DM, Cooper TT, Sherman SE, Seneviratne AK, Hewitt M, Bell GI, et al. Expansion of umbilical cord blood aldehyde dehydrogenase expressing cells generates myeloid progenitor cells that stimulate limb revascularization. Stem Cells Transl Med. 2017;6(7):1607–19.
Álvarez García J, García Gómez-Heras S, Riera Del Moral L, Largo C, García-Olmo D, García-Arranz M. The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue. PeerJ. 2017;5:e3664.
Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92(1):26–36.
The authors gratefully acknowledge the patients that joined this study; Miss Suthathip Jintaworn for data collection; and, Dr. Sasima Tongsai for her assistance with statistical analysis.
This study was funded by a Siriraj Research Grant from the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (Grant No. R016033011).
Ethics approval and consent to participate
The study protocol was approved by the Ethical Review Committee of the Siriraj Institutional Review Board (COA No. 207/2560 [EC4]), and written informed consent was obtained from all patients.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chruewkamlow, N., Pruekprasert, K., Phutthakunphithak, P. et al. Novel culture media enhances mononuclear cells from patients with chronic limb-threatening ischemia to increase vasculogenesis and anti-inflammatory effect. Stem Cell Res Ther 12, 520 (2021). https://doi.org/10.1186/s13287-021-02592-3
- Novel culture media
- Mononuclear cells
- Chronic limb-threatening ischemia
- Anti-inflammatory effect